0000000000986420

AUTHOR

Paola Beltrán

showing 2 related works from this author

Study design of Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS)

2020

Aims: The role of non‐invasive telemedicine (TM) combining telemonitoring and teleintervention by videoconference (VC) in patients recently admitted due to heart failure (HF) (‘vulnerable phase’ HF patients) is not well established. The aim of the Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS) trial is to assess the impact on clinical outcomes of implementing a TM service based on mobile health (mHealth), which includes remote daily monitoring of biometric data and symptom reporting (telemonitoring) combined with VC structured, nurse‐based follow‐up (teleintervention). The results will be compared with those of the comprehensive HF usual care (UC) strateg…

Sintomatología61medicine.medical_specialtyTelemedicineStudy DesignsHospitals -- PacientsAsistencia sanitariaHeart failureInsuficiència cardíaca616.1030204 cardiovascular system & hematologySímptomes03 medical and health sciences0302 clinical medicineAssistència sanitàriaHospitals -- PatientsHealth caremedicineeHealthDiseases of the circulatory (Cardiovascular) systemTransitional careDecompensationTransitional careVideoconferències030212 general & internal medicinemHealthTelecommunication in medicineHospitalizadosStudy Designbusiness.industryVideo conferencingInsuficiencia cardíacaHealth careChronic care modelTelemedicinamedicine.diseaseChronic heart failureTelemedicinemHealthOutcomes researchRC666-701Heart failureVideoconferenciaSymptomsEmergency medicineOutcomes researchCardiology and Cardiovascular MedicinebusinessTelecomunicació en medicinaESC Heart Failure
researchProduct

Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study

2018

Background: Impaired exercise capacity is the most disabling symptom in patients with heart failure with reduced ejection fraction (HFrEF). Despite sacubitril/valsartan showing reduced long-term morbidity and mortality over enalapril in HFrEF, its effects on short-term functional capacity remain uncertain. We sought to evaluate the effects of sacubilril/valsartan on a 30-day six-minute walk test in eligible patients with HFrEF. Methods and results: From November 1, 2016 to February 1, 2017, a total of 58 stable symptomatic patients with HFrEF were eligible for sacubitril/valsartan and underwent 6-MWT before and 30 days after initiation of sacubitril/valsartan therapy. A mixed-effects model …

Malemedicine.medical_specialtyTime FactorsTetrazolesPilot ProjectsWalk Test030204 cardiovascular system & hematologySacubitrilCohort Studies03 medical and health sciencesAngiotensin Receptor AntagonistsElectrocardiography0302 clinical medicineInternal medicineExercise capacityMedicineHumans6-minute walk test030212 general & internal medicineEnalaprilProspective StudiesSacubitril/valsartanAgedAged 80 and overEjection fractionExercise Tolerancebusiness.industryAminobutyratesBiphenyl CompoundsExercise capacityMiddle Agedmedicine.diseaseHeart failure with reduced ejection fractionDrug CombinationsTreatment OutcomeValsartanHeart failureCardiologyValsartanFemaleCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drug
researchProduct